In addition, the TFRC expression in AML cells did not change significantly in two other clinical scenarios, which included those who exhibited progression and those who did not among AML patients administered combined venetoclax and azacitidine treatment (GSE155431, Additional file 1: Fig. S5g) or the responders, partial responders and non-responders among AML patients treated with fedratinib (GSE199455, Additional file 1: Fig. S5h). This evidence concerns the gene TFRC and acute myeloid leukemia.